The company also said it has closed a new $25 million debt facility, and will use the proceeds to retire outstanding debt and bolster the launch of AlloSure.
The algorithm identifies proteins in blood samples taken after bone marrow transplants that predict patients at risk for severe graft-versus-host disease.
The firm missed analyst estimates for revenues and loss per share, citing a continued investment in its AlloSure NGS test for the wider-than-expected loss.
CMDL is usingGenestack's platform to evaluate the effectiveness of bone marrow transplants and plans to use it for other oncology tests as well.
The companies are combining GMSbiotech's proprietary microarray platform with soluble human leukocyte antigen proteins produced by Pure Protein.
An analysis of samples taken a year after kidney transplant identified overlapping gene expression signatures associated with acute and chronic rejection.
Tricare is the healthcare program for active and returned military service members and their families, and covers more than 9 million individuals.
The Dutch firm plans to develop a complete, CE-marked pipeline for NGS-base HLA typing, from DNA amplification to software analysis.
For the Dutch firm, the certifications mark the last step in acquiring the AlleleSEQR product line from Quest subsidiary Celera.
The test is based on the company's TruGraf technology, which analyzes gene expression profiles to detect molecular signatures of acute transplant rejection.
An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.
Research funding in Canada is to remain mostly the same, ScienceInsider reports.
In Science this week: random DNA replication errors play role in cancer, and more.
The Bill and Melinda Gates Foundation embarks on an open-access publishing path.